LIDOCAINE HYDROCHLORIDE VISCOUS

Post-LOE

lidocaine hydrochloride

Molecular Devices

ANDAORALSOLUTION

Approved

Feb 2007

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

LIDOCAINE HYDROCHLORIDE VISCOUS (lidocaine hydrochloride) by Molecular Devices is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 2007.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Hemodynamics: Excessive blood levels may cause changes in cardiac output, total…

Worked on LIDOCAINE HYDROCHLORIDE VISCOUS at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

LIDOCAINE HYDROCHLORIDE VISCOUS

Mechanism of Action

Indications (7)

Clinical Trials (1)